Saitama, Japan

Koichi Ishida

This inventor holds 1 USPTO granted patent. Top assignee: Fuji Yakuhin Co., Ltd. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koichi Ishida. Retrieved from https://idiyas.com/inventor/koichi-ishida-jevp588n

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Koichi Ishida: Innovator in Bisphosphonic Acid Compounds

Introduction

Koichi Ishida is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on bisphosphonic acid compounds. His research aims to address critical health issues related to ectopic calcification.

Latest Patents

Ishida holds a patent for a bisphosphonic acid compound, which is designed to provide a remarkable inhibitory effect on ectopic calcification. The patent describes a novel bisphosphonic acid compound or a salt thereof, along with a pharmaceutical composition that includes this compound. The invention is represented by a specific chemical formula, which includes various structural components that enhance its efficacy.

Career Highlights

Koichi Ishida is associated with Fuji Yakuhin Co., Ltd., where he has been instrumental in advancing pharmaceutical research. His work has not only contributed to the company's portfolio but has also had a broader impact on medical science.

Collaborations

Ishida has collaborated with notable colleagues, including Yoshinobu Aoyagi and Seiichi Kobashi. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Koichi Ishida's contributions to the field of bisphosphonic acid compounds exemplify the importance of innovation in pharmaceuticals. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…